Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.

BMC cancer - 15 Jun 2011

Wang Leiping, Zhang Qunling, Zhang Jian, Sun Si, Guo Haiyi, Jia Zhen, Wang Biyun, Shao Zhimin, Wang Zhonghua, Hu Xichun

Abstract excerpt

BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is the most crucial ErbB receptor tyrosine kinase (RTK) family member in HER2-positive (refered to HER2-overexpressing) breast cancer which are dependent on or "addictive" to the Phosphatidylinositol-3-kinase (PI3K) pathway. HER2-related target drugs trastuzumab and lapatinib have been the foundation of treatment of HER2--positive breast cancer. This...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anthracyclines
Share to Antibiotics, Antineoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Capecitabine

Share to Deoxycytidine

Share to Genes, erbB-2

Share to Lapatinib

Share to Taxoids

Share to Trastuzumab

Source

Open in PubMed Open full text

Identifiers

PMID: 21676217
DOI: 10.1186/1471-2407-11-248
PMCID: PMC3141770

Genes

PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib.PMID 21676217Read ↗

Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.Semantic proximity Read ↗

Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers.Semantic proximity Read ↗

Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone.Semantic proximity Read ↗

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.Semantic proximity Read ↗

Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.Semantic proximity Read ↗

Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.Semantic proximity Read ↗

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.Semantic proximity Read ↗

Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment responseSemantic proximity Read ↗

PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab.Semantic proximity Read ↗

PTEN deficiency as a predictive biomarker of resistance to HER2-targeted therapy in advanced gastric cancer.Semantic proximity Read ↗

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.Semantic proximity Read ↗

PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.